Gilead Sciences appoints Ted Love to Board of Directors

Published On 2024-02-04 05:30 GMT   |   Update On 2024-02-04 05:30 GMT
Advertisement

Foster City: Gilead Sciences, Inc. has announced that Ted Love, MD, has been appointed to the company's Board of Directors.

Dr. Love is currently chair of the Board of Directors of the Biotechnology Innovation Organization and serves on the Boards of Directors of Royalty Pharma and Structure Therapeutics. Previously, he was the President and Chief Executive Officer of Global Blood Therapeutics, Inc. where he led the company from a pre-clinical startup to a global commercial company with a focus on sickle cell disease. Prior, he was Executive Vice President, Research and Development and Technical Operations at Onyx Pharmaceuticals, Inc.; President, Chief Executive Officer and Chairman of Nuvelo, Inc.; and Senior Vice President, Development at Theravance Biopharma, Inc.

Advertisement

He began his biotech career at Genentech. Dr. Love earned his MD from the Yale School of Medicine and completed a residency in Internal Medicine and a fellowship in cardiology at Massachusetts General Hospital.

Dr. Love received the William E. Proudford Sickle Cell Fund 2023 Distinguished Service Award for addressing ongoing healthcare disparities facing the sickle cell disease community. In 2023, he also earned the Spirit of the Heart Health Equity Champion Award from the Association of Black Cardiologists.

Read also: Gilead Kite declares positive trial results of T-cell Therapy Yescarta in Relapsed/Refractory Large B-cell Lymphoma

“We are delighted to welcome Ted Love to the Gilead Board of Directors,” said Daniel O’Day, Chairman and Chief Executive Officer of Gilead Sciences. “Ted is a highly respected executive leader with decades of experience in the biopharma industry, most recently as CEO of a global healthcare company. Ted also has a strong scientific background, and his focus on access and inclusion aligns perfectly with Gilead’s values. Ted will be a valuable addition to the Gilead Board as we continue to expand our impact on patients and communities worldwide.”

Read also: Gilead's Kite, Epic Bio collaborate for development of new cancer therapies

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News